People
Alexander (Sasha) Opotowsky, associate professor at Harvard Medical School and a cardiologist at Boston Children’s Hospital and Brigham and Women’s Hospital took time out to speak with BioSpace about advances in heart health, congenital heart disease (CHD), biopharma, and the Adult Congenital Heart Association (ACHA).
Thomas Wicks, chief strategy officer of New Jersey-based TrialScope, said transparency has picked up over the past few years, particularly as large pharma companies have begun to release information about their own clinical efforts.
In this week’s edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.
After Health and Human Services Secretary Alex Azar, a former executive with Eli Lilly, unveiled a pricing reform that would allow pharma companies to end the rebate system and pass those savings directly to consumers, leaders from across the pharma industry are offering early support for the proposal.
First Light Diagnostics announced the addition of Dr. Peter Kaspar to the company’s board of directors effective January 1, 2019.
Robert Mahley, founder and president of Gladstone Institutes, an internationally-recognized expert on heart disease, cholesterol metabolism and Alzheimer’s disease, is launching a biotech company to focus on Alzheimer’s disease. The company is called GABAeron.
MorphoSys AG announced the appointment of David R. Trexler as President and member of the Board of Directors of MorphoSys US Inc., effective February 6, 2019.
Gilead Sciences reported earnings per share profits for the fourth quarter of $1.44 per share, below analysts’ expectations of $1.70.
$250,000 in Vilcek Foundation Prizes awarded to Angelika Amon, Amit Choudhary, Jeanne Paz, and Mikhail Shapiro
Ultragenyx Pharmaceutical Inc. announced the appointment of Shehnaaz Suliman, M.D., to the company’s Board of Directors, effective January 30, 2019.
PRESS RELEASES